

**sanofi pasteur Statement
FDA Warning Letter
July 3, 2006**

On Friday, June 30, 2006 the FDA issued a warning letter to sanofi pasteur following an annual inspection at the Swiftwater, PA site.

Actions have been underway to address the Agency's findings since the inspection, and we have been reporting our progress weekly during communications with the FDA. To date, many of the FDA's observations have either been resolved or the FDA has accepted our proposed remediation plans. We are working closely with the FDA to bring closure to all remaining concerns.

With regard to the upcoming influenza season, we are confident that we will meet our manufacturing goal of approximately 50 million doses of influenza vaccine for the US market. We identified the testing issue referenced by the FDA early in our production season, and we believe that we have identified necessary corrective measures. The amount of material impacted is minimal relative to our overall manufacturing capacity, and none of this material has been or will be used in the manufacture of this year's vaccine.

Sanofi pasteur is committed to providing our customers with vaccines of the highest purity, potency, and safety. Consistent with our commitment, we take the FDA's recent Warning Letter very seriously. It is important to note that none of the issues raised by the FDA compromises the safety, purity, potency, or supply of any of our products in the market.